Related references
Note: Only part of the references are listed.Inhibition of Nicotine Metabolism by Cannabidiol (CBD) and 7-Hydroxycannabidiol (7-OH-CBD)
Shamema Nasrin et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2023)
Smoking burden, MPOWER, future tobacco control and real-world challenges in China: reflections on the WHO report on the global tobacco epidemic 2021
Kaiping Zhang et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2022)
Population pharmacokinetics of olanzapine in children
Anil R. Maharaj et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2021)
The Impact of Smoking, Sex, Infection, and Comedication Administration on Oral Olanzapine: A Population Pharmacokinetic Model in Chinese Psychiatric Patients
Yan-Nan Zang et al.
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS (2021)
Prediction of steady-state plasma concentrations of olanzapine in Chinese Han in patients based on a retrospective population pharmacokinetic model
Xiaoyue Wang et al.
TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH (2021)
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Matthew J. Page et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
Population Pharmacokinetics of Olanzapine and Samidorphan When Administered in Combination in Healthy Subjects and Patients With Schizophrenia
Lei Sun et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2021)
What to Do About Missed Doses? A Retrospective Study of Olanzapine in the Elderly
Tao Xiao et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2021)
Safety of 80 antidepressants, antipsychotics, anti-attention-deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects
Marco Solmi et al.
WORLD PSYCHIATRY (2020)
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017
C. Hiemke et al.
PHARMACOPSYCHIATRY (2018)
Clinical Pharmacokinetics of Atypical Antipsychotics: An Update
Massimo Carlo Mauri et al.
CLINICAL PHARMACOKINETICS (2018)
Development of a population pharmacokinetic model of olanzapine for Chinese health volunteers and patients with schizophrenia
Anning Li et al.
BMJ OPEN (2018)
Population pharmacokinetics analysis of olanzapine for Chinese psychotic patients based on clinical therapeutic drug monitoring data with assistance of meta-analysis
Anyue Yin et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Sex/gender differences in smoking cessation: A review
Philip H. Smith et al.
PREVENTIVE MEDICINE (2016)
The Impact of Sertraline Co-Administration on the Pharmacokinetics of Olanzapine: A Population Pharmacokinetic Analysis of the STOP-PD
Simon J. C. Davies et al.
CLINICAL PHARMACOKINETICS (2015)
Reporting Guidelines for Clinical Pharmacokinetic Studies: The ClinPK Statement
Salmaan Kanji et al.
CLINICAL PHARMACOKINETICS (2015)
What do we learn from repeated population analyses?
Stephen B. Duffull et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Dose specific effects of olanzapine in the treatment of alcohol dependence
Rae A. Littlewood et al.
PSYCHOPHARMACOLOGY (2015)
Abnormal olanzapine toxicokinetic profiles - population pharmacokinetic analysis
Zofia Tylutki et al.
TOXICOLOGY MECHANISMS AND METHODS (2015)
Kinetic characterization of high-activity mutants of human butyrylcholinesterase for the cocaine metabolite norcocaine
Max Zhan et al.
BIOCHEMICAL JOURNAL (2014)
Reporting a Population Pharmacokinetic-Pharmacodynamic Study: A Journal's Perspective
Kris M. Jamsen et al.
CLINICAL PHARMACOKINETICS (2014)
Gender, acculturation, and smoking behavior among U.S. Asian and Latino immigrants
Bridget K. Gorman et al.
SOCIAL SCIENCE & MEDICINE (2014)
Cannabis and schizophrenia
Benjamin C. McLoughlin et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2014)
Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophrenia
Vidya Perera et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2013)
Pharmacogenetics of olanzapine metabolism
Mao Mao Soderberg et al.
PHARMACOGENOMICS (2013)
Pharmacokinetic-pharmacodynamic modelling of antipsychotic drugs in patients with schizophrenia: Part II: The use of subscales of the PANSS score
Venkatesh Pilla Reddy et al.
SCHIZOPHRENIA RESEARCH (2013)
Pharmacokinetic-pharmacodynamic modeling of antipsychotic drugs in patients with schizophrenia Part I: The use of PANSS total score and clinical utility
Venkatesh Pilla Reddy et al.
SCHIZOPHRENIA RESEARCH (2013)
Drug Metabolism in Older People-A Key Consideration in Achieving Optimal Outcomes With Medicines
Andrew J. McLachlan et al.
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES (2012)
Sex differences in human adipose tissues - the biology of pear shape
Kalypso Karastergiou et al.
BIOLOGY OF SEX DIFFERENCES (2012)
Does Olanzapine Warrant Clinical Pharmacokinetic Monitoring in Schizophrenia?
Erin Schwenger et al.
CLINICAL PHARMACOKINETICS (2011)
Atypical Antipsychotic Metabolism and Excretion
J. J. Sheehan et al.
CURRENT DRUG METABOLISM (2010)
Bioequivalence testing of immunosuppressants: concepts and misconceptions
Uwe Christians et al.
KIDNEY INTERNATIONAL (2010)
Oral Olanzapine Disposition in Adolescents with Schizophrenia or Bipolar I Disorder
Evelyn D. Lobo et al.
PEDIATRIC DRUGS (2010)
Warfarin-dosing algorithm based on a population pharmacokinetic/pharmacodynamic model combined with Bayesian forecasting
Tomohiro Sasaki et al.
PHARMACOGENOMICS (2009)
Hormonal Regulation of Hepatic Drug-Metabolizing Enzyme Activity During Adolescence
M. J. Kennedy
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Metabolism of atypical antipsychotics: Involvement of cytochrome P450 enzymes and relevance for drug-drug interactions
Liana Urichuk et al.
CURRENT DRUG METABOLISM (2008)
Sex, race, and smoking impact olanzapine exposure
Kristin L. Bigos et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Pharmacokinetics and time-course of D2 receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients
A. M. Catafau et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2008)
Clozapine, Olanzapine, or Typical Antipsychotics for Alcohol Use Disorder in Patients With Schizophrenia
Mary F. Brunette et al.
JOURNAL OF DUAL DIAGNOSIS (2008)
Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia
Jiri Horacek et al.
CNS DRUGS (2006)
Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol
SL Sayers et al.
JOURNAL OF NERVOUS AND MENTAL DISEASE (2005)
Assessment of CYP1A2 activity in clinical practice: Why, how, and when?
MS Faber et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2005)
Time response of cytochrome P450 1A2 activity on cessation of heavy smoking
MS Faber et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Dose-dependent alternations in the pharmacokinetics of olanzapine during coadministration of fluvoxamine in patients with schizophrenia
CC Chiu et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Clinical pharmacokinetics of sertraline
CL DeVane et al.
CLINICAL PHARMACOKINETICS (2002)
Fluvoxamine but not sertraline inhibits the metabolism of olanzapine:: Evidence from a therapeutic drug monitoring service
H Weigmann et al.
THERAPEUTIC DRUG MONITORING (2001)
Share Paper
